Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis

Thorax

Volumn 71, Issue 3, 2016, Pages 223-229

  Heltshe, Sonya L ^a,b   Goss, Christopher H ^a,b   Thompson, Valeria ^a   Sagel, Scott D ^c   Sanders, Don B ^d   Marshall, Bruce C ^e   Flume, Patrick A ^f  

^a SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c University of Colorado Denver and Children s Hospital Colorado   (United States)

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^e CYSTIC FIBROSIS FOUNDATION   (United States)

^f MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; ARTICLE; CHILD; CONTROLLED STUDY; CYSTIC FIBROSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LONG TERM CARE; LUNG DISEASE; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PULMONARY EXACERBATION; SHORT COURSE THERAPY; TREATMENT RESPONSE; CLINICAL TRIAL; DISEASE COURSE; FOLLOW UP; INHALATIONAL DRUG ADMINISTRATION; LUNG; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSPECTIVE STUDY; TIME FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ADOLESCENT; ANTI-BACTERIAL AGENTS; CHILD; CYSTIC FIBROSIS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; FORCED EXPIRATORY VOLUME; HUMANS; LUNG; MALE; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84964380423     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2014-206750     Document Type: Article

References (35)

1. Liou TG, Adler FR, Fitzsimmons SC, et al. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol 2001;153:345-52.
2. de Boer K, Vandemheen KL, Tullis E, et al. Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis. Thorax 2011;66:680-5.
3. Sawicki GS, Rasouliyan L, McMullen AH, et al. Longitudinal assessment of health-related quality of life in an observational cohort of patients with cystic fibrosis. Pediatr Pulmonol 2011;46:36-44.
4. Sanders DB, Bittner RC, Rosenfeld M, et al. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med 2010;182:627-32.
5. Briesacher BA, Quittner AL, Fouayzi H, et al. Nationwide trends in the medical care costs of privately insured patients with cystic fibrosis (CF), 2001-2007. Pediatr Pulmonol 2011;46:770-6.
6. Cystic Fibrosis Foundation Patient Registry: Annual Data Report 2012. Bethesda, MD: Cystic Fibrosis Foundation, 2012.
7. Kraynack NC, Gothard MD, Falletta LM, et al. Approach to treating cystic fibrosis pulmonary exacerbations varies widely across US CF care centers. Pediatr Pulmonol 2011;46:870-81.
8. Wagener JS, Rasouliyan L, VanDevanter DR, et al. Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol 2013;48:666-73.
9. Proesmans M, Heyns L, Moons P, et al. Real life evaluation of intravenous antibiotic treatment in a paediatric cystic fibrosis centre: outcome of home therapy is not inferior. Respir Med 2009;103:244-50.
10. Thornton J, Elliott R, Tully MP, et al. Long term clinical outcome of home and hospital intravenous antibiotic treatment in adults with cystic fibrosis. Thorax 2004;59:242-6.
11. Collaco JM, Green DM, Cutting GR, et al. Location and duration of treatment of cystic fibrosis respiratory exacerbations do not affect outcomes. Am J Respir Crit Care Med 2010;182:1137-43.
12. Wolter JM, Bowler SD, Nolan PJ, et al. Home intravenous therapy in cystic fibrosis: a prospective randomized trial examining clinical, quality of life and cost aspects. Eur Respir J 1997;10:896-900.
13. Flume PA, Mogayzel PJ Jr, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med 2009;180:802-8.
14. Blumer JL, Saiman L, Konstan MW, et al. The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis. Chest 2005;128: 2336-46.
15. Parkins MD, Rendall JC, Elborn JS. Incidence and risk factors for pulmonary exacerbation treatment failures in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa. Chest 2012;141:485-93.
16. VanDevanter DR, O'Riordan MA, Blumer JL, et al. Assessing time to pulmonary function benefit following antibiotic treatment of acute cystic fibrosis exacerbations. Respir Res 2010;11:137.
17. Sequeiros IM, Jarad NA. Extending the course of intravenous antibiotics in adult patients with cystic fibrosis with acute pulmonary exacerbations. Chron Respir Dis 2012;9:213-20.
18. Waters V, Stanojevic S, Atenafu EG, et al. Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis. Eur Respir J 2012;40:61-6.
19. Stenbit AE, Flume PA. Pulmonary exacerbations in cystic fibrosis. Curr Opin Pulm Med 2011;17:442-7.
20. Clinical practice guidelines for cystic fibrosis. Bethesda, MD: Cystic Fibrosis Foundation, 1997. Appendix VIII, Table 7.
21. Sagel SD, Thompson V, Chmiel JF, et al. Effect of Treatment of Cystic Fibrosis Pulmonary Exacerbations on Systemic Inflammation. Ann Am Thorac Soc 2015;12:708-17.
22. [No authors listed]. Standardization of Spirometry, 1994 Update. American Thoracic Society. Am J Respir Crit Care Med 1995;152:1107-36.
23. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999;159:179-87.
24. Wang X, Dockery DW, Wypij D, et al. Pulmonary function between 6 and 18 years of age. Pediatr Pulmonol 1993;15:75-88.
25. Goss CH, Edwards TC, Ramsey BW, et al. Patient-reported respiratory symptoms in cystic fibrosis. J Cyst Fibros 2009;8:245-52.
26. Rosenfeld M, Emerson J, Williams-Warren J, et al. Defining a pulmonary exacerbation in cystic fibrosis. J Pediatr 2001;139:359-65.
27. Goss CH, Caldwell E, Gries KS, et al. Validation of a novel patient-reported respiratory symptoms instrument in cystic fibrosis: CFRSD-CRISS. Pediatr Pulmonol 2013;S36:1.
28. Hosmer DW, Lemeshow S. Applied logistic regression. 2nd edn. New York, NY: Wiley, 2000:91-142.
29. Dovey M, Aitken ML, Emerson J, et al. Oral corticosteroid therapy in cystic fibrosis patients hospitalized for pulmonary exacerbation: a pilot study. Chest 2007;132:1212-18.
30. Jarad NA, Sequeiros IM. A novel respiratory symptom scoring system for CF pulmonary exacerbations. QJM 2012;105:137-43.
31. Sequeiros IM, Jarad N. Factors associated with a shorter time until the next pulmonary exacerbation in adult patients with cystic fibrosis. Chron Respir Dis 2012;9:9-16.
32. Morgan WJ, Wagener JS, Yegin A, et al. Probability of treatment following acute decline in lung function in children with cystic fibrosis is related to baseline pulmonary function. J Pediatr 2013;163:1152-7.e2.
33. Goss CH, Burns JL. Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis. Thorax 2007;62:360-7.
34. McCoy KS, Quittner AL, Oermann CM, et al. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med 2008;178:921-8.
35. Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003;290:1749-56.